Serum Metalloproteinases and Their Inhibitors: Markers for Malignant Potential

Overview

Journal Br J Cancer

Specialty Oncology

Date 1994 Sep 1

PMID 8080738

Citations 20

Authors

T Baker

S Tickle

H Wasan

A Docherty

D Isenberg

J Waxman

Affiliations

Soon will be listed here.

Abstract

Death from cancer results from the development of metastases or local progression of tumour. Metastasis and local progression may result from the inappropriate activity of metalloproteinases released by tumour cells or of their regulatory peptides. We have developed quantitative assays for interstitial collagenase, stromelysin 1 and tissue inhibitors of metalloproteinase (TIMP) 1 and 2, which have allowed the study of serum levels of these proteins. Sera from 40 patients with prostatic cancer, stored prior to and after 6 and 12 months' treatment with a gonadotrophin-releasing hormone agonist and an anti-androgen were analysed. Levels were compared with two control groups, comprising 21 patients with active rheumatoid arthritis and 56 age-matched hospital attenders without arthritis or cancer. Contrasting levels have been found in patients with prostatic cancer as compared with hospital controls without cancer and patients with rheumatoid arthritis. Patients with prostatic cancer had higher levels of TIMP-1 and collagenase (P = 0.0001) and lower levels of TIMP-2 (P = 0.003) than controls. Patients with metastatic cancer had significantly higher levels of collagenase than those without metastases (P = 0.02). Patients with rheumatoid arthritis had significantly higher levels of stromelysin than either controls (P = 0.002) or patients with cancer (P = 0.008). Serum tissue inhibitor of metalloproteinase 1 in combination with collagenase levels was as sensitive as prostate-specific antigen as a marker of metastatic disease. These findings provide a basis for the investigation of the role of metalloproteinases and their inhibitors in other malignancies.

Citing Articles

The Role of the Metzincin Superfamily in Prostate Cancer Progression: A Systematic-Like Review.

Binder M, Ward A Int J Mol Sci. 2021; 22(7).

PMID: 33808504 PMC: 8036576. DOI: 10.3390/ijms22073608.

miR-618: possible control over TIMP-1 and its expression in localized prostate cancer.

Ivanovic R, Viana N, Morais D, Moura C, Silva I, Leite K BMC Cancer. 2018; 18(1):992.

PMID: 30340564 PMC: 6194613. DOI: 10.1186/s12885-018-4930-4.

14-3-3 proteins modulate the ETS transcription factor ETV1 in prostate cancer.

Oh S, Shin S, Lightfoot S, Janknecht R Cancer Res. 2013; 73(16):5110-9.

PMID: 23774214 PMC: 3745528. DOI: 10.1158/0008-5472.CAN-13-0578.

Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer.

Kemik O, Kemik A, Sumer A, Dulger A, Adas M, Begenik H World J Gastroenterol. 2011; 17(16):2109-12.

PMID: 21547130 PMC: 3084396. DOI: 10.3748/wjg.v17.i16.2109.

Association of TIMP-4 gene polymorphism with the risk of osteoarthritis in the Korean population.

Lee H, Lee G, Nah S, Lee K, Yang H, Kim Y Rheumatol Int. 2008; 28(9):845-50.

PMID: 18301898 DOI: 10.1007/s00296-008-0545-4.

References

Urbanski S, Edwards D, Maitland A, Leco K, Watson A, Kossakowska A . Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer. 1992; 66(6):1188-94. PMC: 1978055. DOI: 10.1038/bjc.1992.434. View

Lu X, Levy M, Weinstein I, Santella R . Immunological quantitation of levels of tissue inhibitor of metalloproteinase-1 in human colon cancer. Cancer Res. 1991; 51(23 Pt 1):6231-5. View

Waxman J, Wasan H . The architecture of cancer. BMJ. 1992; 305(6865):1306-7. PMC: 1883897. DOI: 10.1136/bmj.305.6865.1306. View

Stearns M, Wang M . Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 1993; 53(4):878-83. View

Torti F . Response criteria in urologic malignancies. Recent Results Cancer Res. 1983; 85:50-7. DOI: 10.1007/978-3-642-81994-0_4. View

Hembry R, Ehrlich H . Immunolocalization of collagenase and tissue inhibitor of metalloproteinases (TIMP) in hypertrophic scar tissue. Br J Dermatol. 1986; 115(4):409-20. DOI: 10.1111/j.1365-2133.1986.tb06235.x. View

Murphy G, Cockett M, Stephens P, Smith B, Docherty A . Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J. 1987; 248(1):265-8. PMC: 1148528. DOI: 10.1042/bj2480265. View

Hewitt R, Leach I, Powe D, Clark I, Cawston T, Turner D . Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer. 1991; 49(5):666-72. DOI: 10.1002/ijc.2910490507. View

Walakovits L, Moore V, Bhardwaj N, Gallick G, Lark M . Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum. 1992; 35(1):35-42. DOI: 10.1002/art.1780350106. View

10.

Pyke C, Ralfkiaer E, Huhtala P, Hurskainen T, Dano K, Tryggvason K . Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res. 1992; 52(5):1336-41. View

11.

Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M . Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res. 1992; 52(16):4548-9. View

12.

Poulsom R, Pignatelli M, Stetler-Stevenson W, Liotta L, Wright P, Jeffery R . Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol. 1992; 141(2):389-96. PMC: 1886613. View

13.

Docherty A, OConnell J, Crabbe T, Angal S, Murphy G . The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol. 1992; 10(6):200-7. DOI: 10.1016/0167-7799(92)90214-g. View

14.

Talhouk R, Bissell M, Werb Z . Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol. 1992; 118(5):1271-82. PMC: 2289583. DOI: 10.1083/jcb.118.5.1271. View

15.

Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G . Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res. 1993; 53(1):165-9. View

16.

Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315-24. DOI: 10.1002/art.1780310302. View

17.

Chowcat N, Savage F, Hembry R, Boulos P . Role of collagenase in colonic anastomoses: a reappraisal. Br J Surg. 1988; 75(4):330-4. DOI: 10.1002/bjs.1800750412. View

18.

Zucker S, Wieman J, Lysik R, Imhof B, Nagase H, Ramamurthy N . Gelatin-degrading type IV collagenase isolated from human small cell lung cancer. Invasion Metastasis. 1989; 9(3):167-81. View

19.

Murphy G, Koklitis P, Carne A . Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yields fully active inhibitor. Biochem J. 1989; 261(3):1031-4. PMC: 1138932. DOI: 10.1042/bj2611031. View

20.

Waxman J, Sandow J, Thomas H, James N, Williams G . A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer. Cancer Chemother Pharmacol. 1989; 25(3):219-20. DOI: 10.1007/BF00689587. View